If you have been reading about lipogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
That'll get taken care of too. It's alright". JD Vance on the same day stated that the ceasefire was actually a "fragile truce". Leavitt confirmed Chinese involvement in truce negotiations with Iran. On 11 April 2026, US Vice President JD Vance with President Trump's special envoy, Steve Witkoff, and son-in-law, Jared Kushner, arrived in Islamabad for peace talks with Iranian officials. The Iranian delegation, which includes Foreign Minister Abbas Araghchi and the speaker of Iran's Parliament Mohammad Bagher Ghalibaf arrived there earlier. On 12 April, Vance left Pakistan, saying that the negotiations had not led to an agreement. Trump told reporters the same day that he did not care about the outcome of the negotiations, instead choosing to spend time at a Ultimate Fighting Championship UFC event with Secretary of State Marco Rubio in Miami, Florida. Following the failure of negotiations, Trump threatened a "full naval blockade" on Iran. The United States Central Command (CENTCOM) announced that the naval blockade would begin on Monday at 10 a.m. EDT which is 5:30 p.m. in Iran. The blockade will be against any vessels that originate or are destined for Iranian ports. Officials clarified that any ships without departure or arrival destinations in Iranian ports will be free to transit the Strait of Hormuz. On 11 April, Trump said that American forces has started "clearing" the Strait of Hormuz. Iran claimed that an American vessel on way to the strait turned backed after warning.
Anatomical model – Three-dimensional representation of human or animal anatomy Body image – Aesthetic perception of one's own body Cell physiology – Study of cell activity Comparative anatomy – Study of similarities and differences in the anatomy of different species Comparative physiology – Study of the diversity of functional characteristics of organisms Development of the human body Glossary of medicine Human physical appearance – Look, outward phenotype Medicine – Diagnosis, treatment, and prevention of illness Organ system Outline of human anatomy The Birth of the Clinic: An Archaeology of Medical Perception
==== Combination drugs ==== Butalbital/acetaminophen (Butapap) – combination of butalbital (GABAA receptor positive allosteric modulator and barbiturate) and acetaminophen (analgesic) Ergotamine/caffeine (Cafergot) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline) and caffeine (adenosine receptor antagonist) Ergotamine/chlorcyclizine/caffeine (Anervan) – combination of ergotamine (non-selective monoamine receptor modulator and ergoline), chlorcyclizine (antihistamine and other actions), and caffeine (adenosine receptor antagonist) Meloxicam/rizatriptan (AXS-07; Symbravo) – combination of meloxicam (COX inhibitor/NSAID) and rizatriptan (triptan) [139] Naproxen sodium/sumatriptan (MT-400; SumaRT/Nap; Suvexx; Trexima; Treximet) – combination of naproxen (COX inhibitor/NSAID) and sumatriptan (triptan) – migraine [140] Paracetamol/codeine/buclizine (Migraleve Yellow) – combination of paracetamol (analgesic) and codeine (opioid) Paracetamol/codeine/buclizine (Migraleve Pink) – combination of paracetamol (analgesic), codeine (opioid), and buclizine (antihistamine and other actions) Paracetamol/dichloralphenazone/isometheptene (Amidrine) – combination of paracetamol (analgesic), dichloralphenazone (phenazone (COX inhibitor/NSAID) and chloral hydrate (GABAA receptor positive allosteric modulator)), and isometheptene (adrenergic receptor agonist) Paracetamol/metoclopramide (Paramax) – combination of paracetamol (analgesic) and metoclopramide (various actions) Sumatriptan/naproxen (Treximet) – combination of sumatriptan (triptan) and naproxen (COX inhibitor/NSAID)
Official website (in Italian) Tourism webpage How to reach Turin? Turin Museums Turin City Card This article incorporates text from a publication now in the public domain: Benigni, Umberto (1912). "Turin". Catholic Encyclopedia. Vol. 15. Turin travel guide from Wikivoyage
In the mitochondrion, pyruvate is oxidized by the pyruvate dehydrogenase complex to the acetyl group, which is fully oxidized to carbon dioxide by the citric acid cycle. Every "turn" of the citric acid cycle produces two molecules of carbon dioxide, one equivalent of ATP guanosine triphosphate (GTP) through substrate-level phosphorylation catalyzed by succinyl-CoA synthetase, as succinyl-CoA is converted to succinate, three equivalents of NADH, and one equivalent of FADH2. NADH and FADH2 are recycled (to NAD+ and FAD, respectively) by oxidative phosphorylation, generating additional ATP. The oxidation of NADH results in the synthesis of 2–3 equivalents of ATP, and the oxidation of one FADH2 yields between 1–2 equivalents of ATP. The majority of cellular ATP is generated by this process. Although the citric acid cycle itself does not involve molecular oxygen, it is an obligately aerobic process because O2 is used to recycle the NADH and FADH2. In the absence of oxygen, the citric acid cycle ceases. The generation of ATP by the mitochondrion from cytosolic NADH relies on the malate-aspartate shuttle (and to a lesser extent, the glycerol-phosphate shuttle) because the inner mitochondrial membrane is impermeable to NADH and NAD+. Instead of transferring the generated NADH, a malate dehydrogenase enzyme converts oxaloacetate to malate, which is translocated to the mitochondrial matrix. Another malate dehydrogenase-catalyzed reaction occurs in the opposite direction, producing oxaloacetate and NADH from the newly transported malate and the mitochondrion's interior store of NAD+.
Sources: en.wikipedia.org
A highly divisive figure, Gaddafi dominated Libya's politics for four decades and was the subject of a pervasive cult of personality. He was decorated with various awards and praised for his anti-imperialist stance, support for Arab—and then African—unity, as well as for significant development to the country after the discovery of oil reserves. Conversely, many Libyans strongly opposed Gaddafi's social and economic reforms; he was accused of various human rights violations. He was condemned by many as a dictator whose authoritarian administration systematically violated human rights and financed terrorism in the region and abroad.
== Properties == nanoCLAMPs are the first antibody mimetics described to be polyol-responsive, meaning they release their targets upon exposure to a non-chaotropic salt and a polyol, such as propylene glycol. This property has been shown to be useful for purifying functional proteins and protein complexes by affinity purification. nanoCLAMPs are easily produced in the cytoplasm of E. coli, with typical yields in the range of 50 to 300 mg/L culture. Because nanoCLAMPs are devoid of cysteines, an engineered C-terminal cysteine can be used for site-directed conjugation of entities like fluorophores or resins using thiol-chemistry.
It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD. The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has Bluetooth integrated into its transmitter, enabling it to send data to a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015. Dexcom went public in 2005 and is listed on the Nasdaq Global Select Market stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the Nasdaq-100, replacing American Airlines Group in the index. The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device. The Dexcom G7 15-Day is the most accurate currently approved CGM in the U.S.
In June 2022, during the annual OECD Ministerial Council Meeting, the Roadmaps for the Accession to the OECD Convention for Brazil, Bulgaria, Croatia, Peru and Romania were adopted. In March 2024, the Roadmaps for the Accession to the OECD were adopted with Argentina and Indonesia, and in July 2024, also with Thailand.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.